Acambis competitor seeks to block shipments of smallpox vaccine to U.S.

08/22/2005 | Guardian (London), The

The only two companies that produce a weakened smallpox vaccine for preventing the disease in the elderly and people with weakened immune systems are competing for a U.S. contract worth $1.9 billion, and are doing battle in court for the contract. Bavarian Nordic, a Swedish biotech, has a lawsuit pending in the U.S. against Acambis, alleging Acambis developed its MVA vaccine with BV's research information and technology, amounting to "misappropriation of trade secrets," and seeks to stop Acambis from exporting its vaccine to the U.S.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA